PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,248,874 | knowledg map target immunotherapi myasthenia gravi bibliometr analysi treatment myasthenia gravi mg advanc steroid tradit immunosuppress target immunotherapi target immunotherapi success employ clinic practic recent year studi aim explor emerg trend target immunotherapi mg summar knowledg structur bibliometr method | D015706;D011642 | T062;T170;T073 |
36,248,873 | character age relat immun featur autolog nk cell infus protocol open label random control trial age usual accompani function declin immun system especi cell respons howev littl known way allevi | D018106;D000072597 | T129;T116;T192 |
36,248,872 | pyroptosi respiratori diseas review current knowledg pyroptosi relat newli discov program cell death accompani inflammatori respons classic view pyroptosi mediat caspas execut gsdmd howev recent demonstr caspas also particip process pyroptosi cleav gsdmde gsdmd respect differ autophagi apoptosi mani pore form cell membran pyroptosi make cell membran lose integr eventu lead releas cytokin interleukin il il bodi infect pathogen expos stimul pyroptosi could play immun defens role found pyroptosi exist wide infecti inflammatori respiratori diseas acut lung injuri bronchial dysplasia chronic obstruct pulmonari diseas asthma excess pyroptosi may accompani airway inflamm tissu injuri airway damag induc inflammatori reaction lead serious damag poor prognosi respiratori diseas review summar relationship pyroptosi relat respiratori diseas | D020382;D000069292 | T129;T116;T043 |
36,248,871 | elev serum cq independ predictor high residu platelet reactiv cad patient receiv clopidogrel therapi inflamm increas risk thrombosi coronari arteri diseas cad patient affect antiplatelet efficaci clopidogrel cq interact platelet activ platelet induc thrombosi particip regul inflammatori respons whether cq affect adenosin diphosph adp induc platelet reactiv clopidogrel therapi unclear studi aim explor issu | D003324;D062645;D013927 | T061;T047;T046 |
36,248,870 | peripher blood marker residu acut leukemia hematopoiet cell transplant use multi plex digit droplet pcr relaps remain primari caus death hematopoiet cell transplant hct acut leukemia abil identifi minimalmeasur residu diseas mrd via blood could identifi patient earlier immunolog intervent may success evalu new test could quantifi blood tumor mrna leukemia mrd surveil use droplet digit pcr ddpcr | D018380;D015470 | T061;T191 |
36,248,868 | pathogen variant ct pleugln adenosin deaminas impair secret elev type ifn respons gene express adenosin deaminas ada homodimer extracellular enzym putat growth factor produc cell myeloid lineag catalyt deamin extracellular adenosin inosin loss catalyt function variant ada gene associ defici ada dada autosom recess diseas associ unusu broad rang inflammatori manifest includ vascul hematolog defect cytopenia previous work group led identif ada variant novel associ dada among uniqu ct pleugln herein refer lq variant locat catalyt domain protein | D000243;D007370 | T129;T121;T126;T116 |
36,248,867 | genet factor under tacrolimus intoler liver transplant tacrolimus fk cornerston immunosuppress liver transplant lt howev clinic switch fk cyclosporin sftc common lt patient tacrolimus intoler aim studi investig genet risk patient tacrolimus intoler | D016031;D016559 | T061;T121;T109 |
36,248,866 | investig influenc breastfeed asthma children year old uk biobank childhood onset asthma coa becom major grow problem worldwid impos heavi socioeconom burden individu famili therefor understand influenc earli life experi breastfeed coa great import earli prevent | D001249;D001942 | T055;T047;T040;T058 |
36,248,865 | combin treatment radiofrequ ablat peptid neoantigen vaccin promis modal futur cancer immunotherapi safeti immunogen person neoantigen base peptid vaccin ineo vac p report previous patient varieti cancer type current studi investig synergist effect radiofrequ ablat rfa neoantigen vaccin cancer patient tumor bear mice | D019496;D009369;D000078703 | T061;T129;T121;T116;T191 |
36,248,864 | sar cov antibodi respons third dose bntb vaccin italian healthcar worker age year one year surveil studi monitor anti spike receptor bind domain rbd neutral antibodi induc pfizerbiontech mrna bntb vaccin cohort healthcar worker age year taken advantag two studi group receiv first two dose time window group hcws receiv third dose month group hcws cohort monitor th day first vaccin dose month third vaccin dose total eight time point year surveil day first dose day second dose month second dose month second dose month second dose month second dose month second dose month third dose group month second dose group month third dose group mean valu anti spike antibodi decreas faster time declin signific slow vs third dose anti spike titer rose fold vs vs booster improv anti spike titer three time compar second dose vs vs differ note two group neutral titer evalu anti spike neutral antibodi found strong correl r p total anti spike antibodi increas third dose howev anti spike titer reach lowest valu neutral antibodi level decreas even repres total anti spike antibodi p find show third vaccin dose improv humor respons wane anti spike neutral antibodi titer time mark neutral antibodi | D000090982;D000086382 | T129;T121;T116;T067;T109;T200;T114;T047 |
36,248,863 | phosphat il concentr predictor long covid hemodialysi patient brazilian studi global burden persist covid hemodialysi hd patient worrisom scenario worth investig critic care chronic kidney diseas ckd perform exploratori post hoc studi trial u two specif aim investig preval covid infect long covid symptom cohort brazilian hd patient ii identifi whether baselin characterist predict long covid sampl | D000086382 | T047;T067 |
36,248,862 | role key transcript factor pu autoimmun diseas pu transcript factor member e transform specif famili affect function varieti immun cell sever physiolog patholog condit previous studi studi role pu patholog condit main focus immun system relat cancer seri articl confirm pu mutat induc varieti immun cell relat malign under mechan also extens valid howev role pu major immun system relat diseas name system autoimmun diseas still unclear recent year research began gradual realiz pu also play import role varieti autoimmun diseas rheumatoid arthriti ra experiment autoimmun encephalomyel eae system lupus erythematosus sle review articl summar find recent studi investig role pu various autoimmun diseas relat under mechan furthermor present new idea provid insight role pu potenti treatment target autoimmun diseas highlight exist research problem futur research direct relat field | D004681;D008180;D009369 | T047;T191;T050 |
36,248,861 | oral manifest serv potenti sign ulcer coliti review immun dysregul relat diseas although ulcer coliti uc primarili affect intestin tract extraintestin manifest diseas evid particular oral caviti herein review various oral present potenti pathogenesi treatment oral lesion relat uc oral manifest uc includ specif nonspecif manifest former includ pyostomat vegetan latter encompass recurr aphthous ulcer atroph glossiti burn mouth syndrom angular cheiliti dri mouth tast chang halitosi periodont although aetiolog uc fulli determin factor lead develop includ immun system dysregul dysbiosi malnutrit principl treat oral lesion uc reliev pain acceler heal lesion prevent secondari infect primari procedur control intestin diseas system corticosteroid prefer treatment option besid topic system administr combin dietari guidanc also appli oral manifest uc might accompani preced diagnosi uc albeit absenc intestin symptom therefor oral lesion especi pyostomat vegetan recurr aphthous ulcer periodont could use good mucocutan sign judg occurr sever uc thus facilit earli diagnosi treatment uc avoid sever consequ colon cancer | D003093;D019226;D013281 | T047 |
36,248,860 | singl cell sequenc reveal effect chemotherapi immun landscap tcrbcr clonal expans relaps ovarian cancer patient cancer recurr chemoresist lead caus death high grade serous ovarian cancer hgsoc patient howev uniqu role immun environ tumor progress relaps chemo resist patient remain elus singl cell resolut character comprehens multi dimension cellular immunolog atlas tumor ascit peripher blood chemo resist patient differ stage treatment result highlight role recurr chemoresist immunosuppress microenviron ascit includ mdsc like myeloid hypo metabol cell peripher cd effector cell chemotherapi induc senescentexhaust import pair tcrbcr sequenc demonstr relat conserv tcr clonal expans hyper expand cd cell extens bcr clonal expans without usag bias v j gene chemotherapi thus studi suggest strategi amelior chemotherapi induc immun impair improv clinic outcom hgsoc | D000970;D010051 | T121;T191;T109 |
36,248,859 | case report bilater panuv resembl vogt koyanagi harada diseas second dose bntb mrna covid vaccin coronavirus diseas covid caus sever acut respiratori syndrom coronavirus sar cov remain serious pandem covid vaccin urgent need limit sar cov outbreak herd immun simultan post market surveil assess vaccin safeti import collect vaccin relat advers event progress vision threaten ophthalm advers event covid vaccin rare matter concern report year old japanes male posit hla drhla drb develop bilater panuv resembl vogt koyanagi harada vkh diseas second dose pfizer biontech covid mrna bntb vaccin glucocorticosteroid gc therapi combin cyclosporin csa readili improv panuv immun profil time onset analyz use cytof technolog reveal activ innat immun main consist natur killer cell acquir immun predomin compos b cell cd cell hand immun profil remiss phase alter gc therapi csa profil compos primarili cd cell consider similar healthi control vaccin result indic bntb vaccin may trigger accident immun cross reactiv melanocyt epitop choroid result onset panuv resembl vkh diseas | D000086382;D015864;D014607 | T047;T067 |
36,248,858 | target hypoxia induc tumor stem activ pathogen induc stem cell nich defens tumor hypoxia oxid stress reprogram cancer stem cell cscs high aggress inflammatori phenotyp state tumor stem previous character tumor stem phenotyp atp bind cassett subfamili g member abcg posit migratori side popul spm fraction cscs expos extrem hypoxia follow reoxygen report post hypoxiareoxygen spmabcg cscs exert defens pathogen invas involv bystand apoptosi non infect cscs vitro assay cancer cell infect bacillus calmett guerin bcg mutant mycobacterium tuberculosi mtb strain b mtb mb pathogen preferenti replic intracellular spmabcg cscs seven cell line divers cancer type includ scc oral squamous cancer cell line condit media cm infect cscs exhibit direct anti microbi activ mtb bcg suggest nich defens pathogen import cm infect cscs exhibit mark vitro bystand apoptosi toward non infect cscs moreov cm treat xenograft bear mice show fold reduct p n number cscs resid hypox nich vitro studi indic bcg infect spmabcg equival epcamabcg cscs scc cell underw pyroptosi releas high mobil group box protein hmgb p death signal tumor microenviron tme death signal induc toll like receptor mediat bystand apoptosi non infect cscs activ pmdm oscil subsequ activ capas depend intrins apoptosi notabl spmabcg sp cell undergo bystand apoptosi amplifi death signal releas hmgbp complex tme result suggest post hypoxia spmabcg cscs serv function role tumor stem defens tsd phenotyp protect tme bacteri invas import cm tsd phenotyp undergo bystand apoptosi may therapeut use cscs resid hypox nich | D024243;D055153 | T123;T116;T022 |
36,248,857 | cuproptosi regul mediat pattern associ immun inltrat featur construct cuproptosi relat signatur guid immunotherapi liver hepatocellular carcinoma hcc preval cancer lack suffici effici approach guid immunotherapi addit cuproptosi recent identifi regul cell death program trigger copper ionophor howev possibl signific tumor immun cell infiltr still unclear | D006528;D008113 | T191 |
36,248,856 | gastrointestin talaromyc marneffei infect patient aid case report systemat review talaromyc marneffei thermal dimorph fungus affect multipl organ frequent invad immunocompromis individu howev studi report presenc intestin infect associ marneffei herein report case intestin marneffei infect man complain month histori intermitt fever abdomin pain diarrhea result human immunodefici virus antibodi test posit period acid schiff gomorrah methylamin silver stain intestin biopsi tissu reveal marneffei infect fortun patient symptom rapid resolv prompt antifung treatment addit summar describ clinic characterist manag outcom patient intestin marneffei infect total patient identifi major comorbid acquir immunodefici syndrom main clinic featur includ anemia fever abdomin pain diarrhea weight loss lymphadenopathi transvers descend colon ileocecum ascend colon common site lesion consider number patient develop intestin obstruct intestin perfor gastrointestin bleed patient six underw surgeri surviv success antifung treatment five die marneffei infect one die unknown caus marneffei intestin infect consid immunodefici patient endem area present non specif symptom fever abdomin pain diarrhea appropri time endoscopi avoid delay diagnosi earli aggress antifung therapi improv clinic outcom patient | D017088;D000163 | T047 |
36,248,855 | role astrocyt subarachnoid hemorrhag therapeut implic subarachnoid hemorrhag sah import public health concern high morbid mortal worldwid sah induc cell death blood brain barrier bbb damag brain edema oxid stress abund cell type central nervous system astrocyt play essenti role brain damag recoveri follow sah review describ astrocyt activ polar sah astrocyt mediat bbb disrupt glymphat lymphat system dysfunct oxid stress cell death sah furthermor astrocyt engag abund crosstalk brain cell endotheli cell neuron pericyt microglia monocyt sah addit astrocyt also exert protect function sah final summar evid regard therapeut approach aim modul astrocyt function follow sah could provid new lead futur translat therapi allevi damag sah | D013345 | T047;T046 |
36,248,854 | central role pd l cardioprotect result py nucleotid receptor loss better understand immun function pericardi adipos tissu essenti adapt treatment myocardi infarct show previous inactiv mous py nucleotid receptor induc adiponectin overexpress protect myocardi infarct investig inflammatori state pericardi adipos tissu ischem py defici mice demonstr py defici mice display adipocyt beig increas pd l express higher number regulatori leukocyt pericardi adipos tissu left anterior descend arteri ligat compar wild type mice effect higher level anti inflammatori mc macrophag regulatori cell observ pericardi adipos tissu py ko mice correl reduc post ischem expans fat associ lymphoid cluster interest anti inflammatori effect observ py ko mice observ py adiponectin doubl ko ischem mice final reduct cell infiltr cardiac fibrosi observ py defici heart lost inject anti pd l block antibodi ischem mice present studi defin py regul pd l adiponectin potenti target anti inflammatori therapi improv myocardi infarct outcom combin effect py loss adipocyt beig regulatori leukocyt increas highlight nucleotid receptor import player post ischem cardiac respons | D052242;D009203 | T123;T047;T116 |
36,248,853 | identif valid ferroptosi relat lncrna signatur prognost model skin cutan melanoma melanoma type skin cancer origin malign transform epiderm melanocyt extrem high lethal ferroptosi document high relat cancer pathogenesi effect immunotherapi addit dysregul lncrnas great implic melanoma progress ferroptosi regul howev signific ferroptosi relat lncrna melanoma treatment prognosi melanoma patient remain elus | D000079403;D008545;D062085;D012878 | T123;T191;T114;T043 |
36,248,852 | role complement nonalcohol fatti liver diseas nonalcohol fatti liver diseas nafld becom lead caus chronic liver diseas global nafld includ rang hepat manifest start liver steatosi potenti evolv toward nonalcohol steatohepat cirrhosi even hepatocellular carcinoma although pathogenesi nafld incomplet understood insulin resist lipid metabol disord implic complement system essenti part immun system also involv lipid metabol particular activ altern complement pathway product complement activ product ca cadesarg acyl stimul protein asp ca strong associ insulin resist lipid metabol disord hepat inflamm review briefli summar research role complement system nafld aim provid basi develop novel therapeut strategi nafld | D007333;D065626 | T047;T046 |
36,248,851 | impact adjuv trival vaccin quadrival like protect heterolog yamagata lineag influenza b virus new vaccin technolog platform nanoparticl novel adjuv develop aid establish univers influenza vaccin studi tradit influenza splitsubunit vaccin overlook commerci avail vaccin typic studi term influenza h h virus influenza b virus need examin well thus need understand limit splitsubunit vaccin develop strategi overcom limit particular abil elicit cross reactiv antibodi co circul victoria b v yamagata b lineag human influenza b virus studi compar three commerci influenza hemagglutinin ha splitsubunit vaccin one quadrival h h b v b two trival h h b v character potenti differ antibodi respons protect b challeng found trival adjuv vaccin fluad formul without b ha abl produc antibodi b cross lineag similar level elicit quadrival vaccin flucelvax contain b v b interest fluad protect mice lethal cross lineag b viral challeng anoth trival vaccin fluzon hd fail elicit antibodi full protect follow challeng fluad immun also diminish viral burden lung compar fluzon salin group success trival vaccin provid protect cross lineag influenza b challeng similar quadrival vaccin suggest analysi differ splitsubunit vaccin formul could identifi mechan vaccin target antigen differ virus understand increas breadth immun respons follow immun need univers influenza vaccin develop | D007252;D007251 | T129;T047;T121;T109 |
36,248,850 | innat immun checkpoint inhibitor resist associ melanoma sub type exhibit invas de differenti gene express signatur melanoma high aggress skin cancer although high immunogen frequent escap bodi immun defenc immun checkpoint inhibitor ici anti pd anti pdl anti ctla antibodi lead reactiv immun pathway promot reject melanoma howev benefit ici therapi remain limit relat small proport patient exhibit ici resist moreov precis mechan under innat acquir ici resist remain unclear investig differ melanoma tissu respond non respond patient anti pd therapi term tumour immun cell gene associ signatur perform multi omic investig melanoma tumour tissu collect patient start treatment anti pd immun checkpoint inhibitor patient subsequ categor respond non respond anti pd therapi base recist criteria multi omic analys includ rna seq nanostr analysi rna seq data carri hla phenotyp well gene enrich analysi pathway enrich analysi immun cell deconvolut studi consist previous studi data show respond anti pd therapi higher immun score median immun score respond median immun score non respond p valu mann whitney u two tail exact test compar non respond respond melanoma high enrich combin cd cell dendrit cell p valu subtyp macrophag p valu addit melanoma respond patient exhibit differenti gene express pattern high prolif low invas associ gene express signatur wherea tumour non respond exhibit high invas frequent neural crest like cell type gene express signatur find suggest non respond melanoma anti pd therapi exhibit de differenti gene express signatur associ poorer immun cell infiltr establish gene express pattern characterist innat resist anti pd therapi improv understand tumour intrins gene express pattern associ respons anti pd therapi help identifi predict biomark ici respons may help identifi new target anticanc treatment especi capac function adjuv improv ici outcom | D008545;D012878 | T191 |
36,248,849 | cytokin network acut myeloid leukemia acut myeloid leukemia aml high heterogen malign blood bone marrow character clonal expans myeloid stem progenitor cell rapid diseas progress chemotherapi first line treatment aml year applic recent high throughput next generat sequenc technolog reveal signific molecular heterogen aml turn motiv effort develop new target therapi howev due high complex diseas includ multipl driver mutat coexist multipl compet tumorigen clone success incorpor new agent clinic practic remain challeng continu difficulti call identif innov therapeut approach effect larger cohort aml patient recent studi suggest chronic immun stimul aberr cytokin signal act trigger aml initi progress facet diseas might exploit promis target aml treatment howev despit greater appreci cytokin profil aml exact function cytokin aml pathogenesi fulli understood therefor unravel molecular basi complex cytokin network aml prerequisit develop new therapeut altern base target cytokin receptor | D015470 | T191 |
36,248,848 | transcript state car infus relat neurotox lesson high resolut singl cell som express portray anti cd car cell immunotherapi hope treatment option patient b cell lymphoma howev cope part sever advers effect like neurotox singl cell resolv molecular data set combin clinic parametr allow comprehens character cellular subpopul transcriptom state relat advers effect present analysi singl cell rna sequenc data patient compris cell focus cellular state associ immun cell relat neurotox develop singl cell data portray workflow disentangl transcript state space singl cell resolut analysi term modular compos cellular program demonstr capabl singl cell data portray disentangl transcript state use intuit visual function mine molecular cell stratif variabl analys analysi reveal cell composit patient infus product well spectrum transcript state cell deriv patient low ican grade mark differ cell high ican patient relat abund particular cycl cell lag mediat exhaust car posit cell vari studi provid molecular detail transcriptom landscap possibl impact overcom neurotox | D020258;D000076962 | T129;T116;T037;T192 |
36,248,847 | modul urelumab glycosyl separ immun stimulatori activ organ toxic checkpoint control immunomodulatori antibodi becom import tool modul tumor self reactiv immun respons major issu prevent make full use potenti immunomodulatori antibodi sever side effect rang system cytokin releas syndrom organ specif toxic igg fc portion demonstr contribut desir well undesir antibodi activ checkpoint control immunomodulatori antibodi via bind cellular fc receptor fcr thus choos igg subclass human igg low abil interact fcrs identifi potenti strategi limit fcr complement pathway depend side effect howev even immunomodulatori antibodi human igg background may interact cellular fcrs show dose limit toxic use human mous model allow studi immunomodulatori activ human checkpoint control antibodi vivo demonstr deglycosyl cd specif igg antibodi urelumab result amelior liver toxic maintain cell stimulatori activ addit result emphas antibodi dose impact separ side effect urelumab therapeut activ via igg deglycosyl thus glycoengin human igg antibodi may possibl approach limit collater damag immunomodulatori antibodi allow greater therapeut window opportun | D000911;D017452 | T129;T116;T192 |
36,248,846 | plasma proteom respons zebrafish follow carrageenan induc inflamm mediat pmn leukocyt correl high human counterpart regul inflamm critic process maintain physiolog homeostasi carrageenan cgn mucopolysaccharid extract cell wall red alga chondrus crispus capabl induc acut intestin inflamm translat product acut phase reactant secret blood circul howev associ mechan vertebr well understood investig crucial factor behind inflammatori milieu cgn mediat inflamm administ vw ip inject periton caviti adult zebrafish zf danio rerio found polymorphonuclear leukocyt neutrophil lymphocyt infiltr zf periton caviti short term persist nevertheless generat strong pattern inflamm affect system enough produc edema caviti consist find cell infiltr caus notabl tissu chang result overexpress sever acut inflammatori marker protein level use revers phase high perform liquid chromatographi follow hybrid linear ion trap mass spectrometri shotgun proteom approach identifi plasma protein among anim inject pbs cgn first bioinformat analysi reveal composit plasma proteom interest common express protein record among treat control group surpris novel protein differenti express exclus cgn induc group furthermor common express protein compar control group protein got signific p upregul cgn treat group remain ten protein downregul next obtain major protein protein interact network hub protein cluster blood plasma cgn induc group moreov understand molecular underpin effect base unveil protein set perform bioinformat structur similar analysi generat overlap reconstruct zf human acut inflamm biolog pathway analysi point activ abund divers classic immun acut phase reactant sever catalyt enzym vari protein support immun respons togeth inform use test find novel pharmacolog target treat human intestin inflammatori diseas | D007962;D020543;D015027 | T123;T116;T025;T013 |
36,248,845 | singl cell meta analysi endmt emt state covid covid prognos suggest proport patient develop fibrosi evid indic whether patient progress mesenchym transit mt lung role mt covid pandem remain poor understood use singl cell rna sequenc profil transcriptom cell lung healthi individu n covid patient n idiopath pulmonari fibrosi ipf patient n human lung map entir mt chang analysi enabl us map high resolut matrix produc cell identifi distinct subpopul endotheli cell ec epitheli cell primari cellular sourc mt cluster covid first time identi earli late subgroup endotheli mesenchym transit endmt epitheli mesenchym transit emt use analysi public databas singl cell sequenc assess epitheli subgroup age smoke status gender data suggest proport chang emt covid statist signific enumer earli late emt suggest correl invas gene covid final endmt upregul covid patient enrich inflammatori cytokin classifi endmt earli late stage found earli endmt posit correl entri factor true late endmt explor mt state may help mitig fibrosi impact sar cov infect | D000086382;D058750 | T047;T067;T043 |
36,248,844 | identif cross talk pathway ferroptosi relat gene periodont type diabet mellitus bioinformat analysi experiment valid bidirect relationship periodont type diabet mellitus tdm aim studi explor pathogenesi comorbid screen ferroptosi relat gene involv patholog process predict potenti drug target develop new therapeut strategi | D003924;D000079403;D010518 | T047;T043 |
36,248,843 | distinct spatial distribut role kupffer cell monocyt deriv macrophag mous acut liver injuri macrophag key regul inflamm repair heterogen multipl role liver fulli understood aim herein map intrahepat macrophag popul function acut liver injuri use flow cytometri gene express analysi multiplex immunofluoresc reconstruct spatial imag analysi character intrahepat immun landscap mice post ccl induc acut liver injuri three distinct phase necroinflamm earli late repair observ hepatocellular necrosi reduct liver resid lymphocyt necroinflamm accompani infiltr circul myeloid cell upregul inflammatori cytokin paramet return baselin level repair phase pro repair chemokin upregul identifi resid clecf kupffer cell kcs infiltr iba clecf monocyt deriv macrophag momf main hepat macrophag popul respons injuri occupi necrot area kcs momf exhibit distinct kinet distribut morpholog site injuri necroinflamm phase character low level kcs remark invas momf suggest potenti role phagoctos necrot hepatocyt opposit kineticsdistribut observ repair earli repair phase yolksac deriv kcs restor wherea momf diminish gradual dissip late repair momf interact hepat stellat cell necroinflammatori earli repair phase potenti modul activ state influenc fibrogen pro repair function critic wound heal altogeth studi reveal novel distinct spatial tempor distribut kcs momf provid insight complementari role acut liver injuri | D007728;D008099 | T023;T025 |
36,248,842 | dysfunct purinerg signal correl diseas sever covid patient ectonucleotidas modul inflammatori respons balanc extracellular atp adenosin ado might involv covid immunopathogenesi explor contribut extracellular nucleotid metabol covid sever mild sever case diseas verifi gene express ectonucleotidas reduc whole blood patient covid negat correl level crp inflammatori marker diseas sever line find covid patient present higher atp level plasma reduc level ado compar healthi control cell type specif analysi reveal higher frequenc cd cell sever ill patient cd cd express cd reduc group frequenc b cell cdcd also decreas acut covid interest b cell covid patient show reduc capac hydrolyz atp adp ado furthermor impair express ado receptor compromis activ signal pathway observ covid patient presenc ado vitro howev suppress inflammatori respons trigger patient cell summari find support idea alter metabol extracellular purin contribut immun dysregul covid possibl favor diseas sever suggest ado may therapeut approach diseas | D000086382 | T047;T067 |
36,248,841 | ptprdptprt mutat predict biomark immun checkpoint inhibitor across multipl cancer type immun checkpoint inhibitor ici dramat chang treatment landscap varieti cancer nevertheless variabl ici respons highlight import identifi predict biomark ptprd ptprt ptprdptprt phosphatas jak stat signal critic pathway anti cancer immun regul howev pan cancer associ ptprdptprt mutat efficaci ici remain unclear across pan cancer patient | D000074322;D002289;D008175 | T129;T121;T191;T116 |
36,248,840 | msc ev transfer mitochondria relat compon new hope treatment kidney diseas kidney diseas serious hazard human health acut chronic renal diseas signific negat impact bodi metabol involv mitochondria renal ill receiv lot interest research kidney diseas advanc extracellular vesicl gain popular mean intercellular communic recent year close connect nephropathi process intercellular transfer mitochondria goal review present extracellular vesicl transport mitochondria relat biolog activ molecul new therapeut option treatment clinic kidney diseas review focus extracellular vesicl transfer mitochondria relat bioactiv molecul affect mitochondri energi metabol take part immun regul secret outsid bodi | D000067128;D051436 | T026;T047 |
36,248,839 | landscap circul metabol fingerprint keloid keloid fibroprolif diseas character unsatisfactori therapeut effect high recurr rate | D007627 | T020 |
36,248,838 | function omega polyunsatur fatti acid respons cadmium exposur throughout histori pollut becom part daili life improv life qualiti advanc industri heavi industri recent year advers effect heavi metal cadmium cd human health wide discuss particular immun system review summar avail evid cd exposur may affect health analyz general manifest inflamm caus cd exposur find role omega n polyunsatur fatti acid pufa vivo counteract cd induc harm addit elucid effect n pufa immun system analyz prophylact therapeut effect cd exposur overal review highlight role n pufa patholog chang induc cd exposur although n pufa remain verifi whether use therapeut agent rehabilit therapi supplement n pufa reliabl effect | D002104;D015525 | T121;T123;T109;T131;T196 |
36,248,837 | independ interact effect eye rub atopi keratoconus evalu independ interact effect eye rub atopi keratoconus kc central china | D006969;D007640 | T047;T046 |
36,248,836 | case report autoimmun nodopathi concurr serum csf igg anti neurofascin antibodi report case autoimmun nodopathi concurr serum csf immunoglobulin ig g anti neurofascin nf anti gdb antibodi | D007074;D020277 | T129;T047;T121;T116 |
36,248,835 | steril protect transmiss blockad multistag anti malari vaccin pre clinic studi malaria vaccin technolog roadmap world health organ aim develop safe effect vaccin offer least protect efficaci clinic malaria reduc parasit transmiss demonstr high effect multistag vaccin pre erythrocyt sexual stage plasmodium falciparum protect reduc transmiss murin model vaccin base viral vector vaccin platform compris high attenu vaccinia virus strain lcm genet stabl variant licens high effect japanes smallpox vaccin lcm adeno associ virus aav viral vector human gene therapi gene encod p falciparum circumsporozoit protein pfcsp ookinet protein p pfs express pfs pfcsp fusion protein heterolog primeaav boost immun regimen mice provid protect pfcsp transgen p berghei sporozoit transmiss block efficaci determin direct membran feed assay use parasit p falciparum posit natur infect donor endem set remark persist vaccin induc immun respons month addit provid complet protect repeat parasit challeng murin model propos applic maav malaria multistag vaccin platform potenti contribut landmark goal malaria vaccin technolog roadmap achiev life long steril protect high level transmiss block efficaci | D000962;D017780;D016778 | T129;T121;T047 |
36,248,834 | cannabidiol modul express type ifn respons gene hiv infect macrophag cannabi cannabi sativa wide use drug unit state frequenc cannabi use particular high among peopl live hiv plwh one key compon cannabi non psychotrop cannabidiol cbd exert wide varieti biolog action includ anticonvuls analges anti inflammatori effect howev exact mechan action cbd affect immun cell signal remain poor understood report cbd modul type interferon respons human macrophag transcriptom analysi show cbd treatment signific attenu cgas sting mediat activ type interferon respons gene isg monocyt thp cell show cbd treatment effect attenu cgamp stimul isg thp cell primari human macrophag interest cbd signific upregul express autophagi receptor psqstm p critic autophagi mediat degrad stimul sting observ cbd treat thp cell elev autophagi activ upon cgamp stimul cbd treat cell rapid downregul phosphoryl sting lead attenu express isg cbd attenu isg reduc autophagi defici thp cell suggest effect cbd isg partial mediat autophagi induct last cbd decreas isg express upon hiv infect thp cell human primari macrophag lead increas hiv rna express hour infect howev long term cultur cbd infect primari macrophag reduc hiv viral spread suggest potenti dichotom role cbd hiv replic studi highlight immun modulatori effect cbd need addit studi effect viral infect inflamm | D002185;D015658;D007370 | T129;T121;T116;T109;T047 |
36,248,833 | case report consist diseas manifest stagger time cours two ident twin affect adenosin deaminas defici defici adenosin deaminas dada autosom recess diseas associ high variabl clinic present includ vascul immunodefici hematolog manifest potenti progress time present studi describ long term evolut immuno hematolog featur therapeut challeng two ident adult twin sister affect dada absenc plasmat adenosin deaminas ada activ twin suggest diagnosi dada confirm genet analysi exon sequenc reveal missens pleupro mutat patern ada allel whole genom sequenc identifi unreport delet ivsivsdel matern allel predict produc transcript miss exon patient experienc diseas onset childhood earli stroke patient two year patient eight year age subsequ follow share dada associ featur includ neutropenia hypogammaglobulinemia reduc switch memori b cell invert cd cd ratio increas nave cell reduc follicular regulatori cell almost complet absenc nk cell larg granular cell leukemia osteoporosi diseas evolut differ clinic manifest present sever year earlier pronounc patient patient due g csf refractori life threaten neutropenia patient success underw urgent hematopoiet stem cell transplant hsct match unrel donor patient experienc similar although delay diseas evolut current anti tnf therapi anti infecti prophylaxi uniqu case confirm heterozyg patient null ada activ deserv deep investig possibl structur variant singl allel moreov report emphas import time recogn dada onset allow adequ follow detect diseas progress final therapeut manag ident twin rais signific concern share similar phenotyp delay almost predict diseas evolut one could benefit prompt definit treatment like elect allogen hsct addit data requir assess whether absenc enzymat activ diagnosi associ hematolog involv also predict bone marrow dysfunct encourag earli hsct improv function outcom | D000361;D009503;D010488 | T047 |
36,248,832 | sex hormon intestin inflamm gut microbiom major influenc sexual dimorph obes obes defin excess accumul bodi fat associ increas risk develop major health problem cardiovascular diseas diabet stroke clear sexual dimorph epidemiolog pathophysiolog sequela obes accompani metabol disord femal often better protect compar male protect predomin attribut femal sex hormon estrogen differ fat distribut recent sexual dimorph obes also attribut differ composit function gut microbiota intestin immun system review comprehens summar pre clinic clinic evid sexual dimorph discuss interplay sex hormon intestin inflamm gut microbiom obes major gap limit rapid grow area research also highlight review | D005768;D000069196 | T125;T007;T001 |
36,248,831 | persist dysfunct mucos sar cov specif iga low lung il associ covid fatal outcom cross section analysi role mucos pulmonari antibodi respons coronavirus diseas covid outcom remain unclear found bronchoalveolar lavag bal sampl patient sever covid infect ancestr wuhan virus mucos igg iga specif receptor bind domain rbd nucleocapsid protein np emerg bal contain virus earli infect persist virus elimin iga igg antigen test furthermor spike iga spike igg immun complex detect bal especi lung virus clear bal igg iga recogn four main rbd variant bal neutral titer higher earli covid virus replic lung later infect viral clearanc patient fatal covid contrast survivor develop higher level mucos spike specif iga igg lost neutral activ time reduc il lung altogeth mucos spike np specif igg specif iga persist lung sever acut respiratori syndrom coronavirus sar cov clearanc low pulmonari il correl covid fatal outcom thus mucos sar cov specif antibodi may advers function addit protect neutral | D000086382;D000086402 | T047;T005;T067 |
36,248,830 | acut stress induc inflamm domin innat immun repres neutrophil mice well known psycholog stress could affect immun system regul diseas process previous studi most focus effect chronic stress diseas immun cell acut stress affect immun system remain poor understood studi hour restraint stress stress rna extract mous peripher blood follow sequenc bioinformat analysi found compar control group differenti express gene stress group main display regul express gene set enrich analysi result show enrich gene term main relat inflammatori respons defens respons wound respons wound heal complement activ pro inflammatori cytokin product term cell activ differenti chemotaxi enrich gene term relat varieti immun cell among neutrophil seem activ stress respons result gene set variat analysi show acut stress inflammatori reaction domin innat immun form addit concentr serum il il increas signific acut stress indic bodi inflammatori state import found acut stress led signific increas number neutrophil peripher blood number cell b cell decreas signific flow cytometr analysi protein protein interact network analysi screen hub gene main relat inflamm neutrophil also found acut stress led regul ccr ccr xcr cxcr gene involv cell migrat chemotaxi data suggest immun cell readi infiltr tissu emerg blood vessel acut stress hypothesi support lps induc acut inflammatori model hour lps treatment flow cytometr analysi show lung mice acut stress character increas neutrophil infiltr decreas cell b cell infiltr immunohistochem analysi also show acut stress led sever lung inflamm mice receiv repeat acut stress lps stimul surviv rate signific lower mice stimul lps altogeth acut stress led rapid mobil immun system bodi present inflammatori state domin innat immun respons repres neutrophil | D008070;D009504 | T025;T109 |
36,248,829 | vitamin c defici reveal development differ neonat adult hematopoiesi hematopoiesi process result differenti blood lineag essenti throughout life product x blood cell per day includ x erythrocyt high depend nutrient consumpt notabl though relat requir micronutri perinat period critic development window immun cell erythrocyt differenti extens studi specif impact vitamin cascorb micronutri perinat compar adult hematopoiesi difficult assess anim model even though human synthes ascorb due pseudogen l gulono lacton oxidas gulo gene generat glucos ancestr mammalian trait take advantag gulo mous model show ascorb acid defici profound impact perinat hematopoiesi result hypocellular bone marrow bm signific reduct hematopoiet stem cell multipot progenitor hematopoiet progenitor furthermor myeloid progenitor exhibit differenti sensit vitamin c level common myeloid progenitor megakaryocyt erythrocyt progenitor mark reduc gulo pup follow vitamin c deplet dam wherea granulocyt myeloid progenitor spare frequenc even augment notabl hematopoiet cell subset rescu vitamin c replet consist data peripher myeloid cell maintain ascorb defici gulo pup lineag commit hematopoiet cell decreas reduct b cell number associ signific reduc humor immun respons ascorb deplet gulo pup adult mice erythropoiesi particular sensit vitamin c depriv perinat adult period ascorb defici gulo pup well adult mice exhibit compensatori splenic differenti furthermor patholog context hemolyt anemia vitamin c defici adult gulo mice abl suffici increas erythropoiet activ result sustain anemia thus vitamin c play pivot role mainten differenti hematopoiet progenitor neonat period requir throughout life sustain erythroid differenti stress condit | D001206;D045969;D012614 | T047;T015 |
36,248,828 | understand inborn error immun len pathophysiolog monogen inflammatori bowel diseas inflammatori bowel diseas ibd chronic inflammatori condit gastrointestin tract includ crohn diseas ulcer coliti inflammatori bowel diseas undefin ibd u ibd understood multifactori involv genet immun microbi environment factor advanc next generat sequenc facilit grow identif monogen caus ibd mani overlap inborn error immun iei approxim third current identifi iei result gastrointestin manifest mani inflammatori natur ibd inde gastrointestin tract repres opportun system studi iei consist largest mass lymphoid tissu bodi employ thin layer intestin epitheli cell critic barrier intestin lumen host mini review select pertin iei result monogen ibd describ involv disord intestin epitheli barrier phagocytosi b cell defect well impair central peripher toler contribut disrupt gut microbiota host interact disturb intestin homeostasi among patient intestin diseas also discuss molecular mechan drive pathogenesi review along person therapeut intervent investig avenu grow knowledg enabl | D003093;D003424;D015212 | T047 |
36,248,827 | immunogen cell death relat risk model delin ferroptosi pathway predict immunotherapi respons patient gbm immunogen cell death icd type cell death lead regul activ immun respons mark exposur deliveri damag associ molecular pattern damp tumor microenviron accumul evid reveal signific icd relat gene tumor progress therapeut respons studi obtain two icd relat cluster glioblastoma gbm appli consensus cluster construct risk signatur account prognost icd gene base risk signatur found higher risk score associ wors patient prognosi besid result illustr ferroptosi regulatorsmark high enrich high risk group ferroptosi correl cytokin signal pathway immun relat pathway also discov high risk score correl specif immun infiltr pattern good respons immun checkpoint blockad icb treatment conclus studi highlight signific icd relat gene prognost biomark immun respons indic gbm risk signatur integr prognost gene possess signific potenti valu predict prognosi patient efficaci icb treatment | D000079403;D005909 | T191;T043 |
36,248,826 | type autoimmun hepat genet suscept two type autoimmun hepat aih recogn aih character presenc anti nuclear andor anti smooth muscl autoantibodi aih associ presenc anti liver kidney microsom andor anti liver cytosol antibodi autoantigen target aih autoantibodi cytochrom p formiminotransferas cyclodeaminas anti lkm anti lc respect autoantigen express hepatocyt higher level cell type therefor compar aih autoantigen target aih predomin tissu specif distinct clinic featur specif aih compar aih includ diagnosi younger patient mean age year onset fulmin hepat young patient year age less higher frequenc children adult frequent associ extrahepat cell mediat autoimmun diseas aih also often diagnos patient primari immunodefici aih associ specif hla class ii suscept allel dqb consid main determin suscept drb drb associ type autoantibodi present hla dqb strong linkag disequilibrium hla drb drb interest human mhc non mhc gene strong influenc develop diseas anim model aih altogeth find suggest aih incid like depend specif genet suscept factor combin distinct environment trigger | D019693 | T047 |
36,248,825 | metabolom base investig sar cov vaccin sinovac reveal immun depend metabolit biomark sar cov mutant strain continu rapid spread high infect fatal larg scale sar cov vaccin provid import guarante effect resist exist mutat sar cov virus infect howev whether host metabolit level respond sar cov vaccin influenc host immun remain unclear help delin serum metabolom profil sar cov vaccin volunt determin metabolit tight respond host immun antibodi cytokin studi total sera sampl collect individu sar cov vaccin covid vaccin week two dose vaccin next untarget metabolom perform distinct metabol composit reveal pre vaccin vb group two dose vaccin sv group partial least squar discrimin princip compon analys base criteria fdr found l glutam acid gamma aminobutyr acid gaba succin acid taurin show increas trend sv vb furthermor sv associ metabolit main annot butano metabol glutam metabol pathway moreov two metabolit biomark classifi sv vb individu area curv auc correl analysi identifi posit associ four metabolit enrich glutam metabol serum antibodi relat igg igm iga result suggest content gamma aminobutyr acid indol serum could appli biomark distinguish vaccin volunt unvaccin metabolit gaba taurin may serv metabol target adjuv vaccin boost abil individu improv immun | D000086382;D014765 | T129;T047;T121;T067 |
36,248,824 | ose complotyp clinic potenti cellular death age tissu damag trigger inflamm lead enzymat non enzymat lipid peroxid polyunsatur fatti acid present cellular membran lipoprotein result generat high reactiv degrad product malondialdehyd mda hydroxynonen hne coval modifi free amino group protein lipid vicin newli generat neoepitop repres uniqu set damag associ molecular pattern damp associ oxid stress term oxid specif epitop ose ose enrich oxid lipoprotein microvesicl die cell trigger steril inflamm therefor prompt recognit remov ose requir maintain homeostat balanc partial achiev various humor compon innat immun system natur igm antibodi pentraxin complement compon bind ose case modul pro inflammatori potenti natur igm antibodi potent complement activ recogn ose oxid phosphocholin oxpc hne mda epitop furthermor oxpc epitop bind complement activ pentraxin c reactiv protein mda epitop bound cq ca complement factor h cfh complement factor h relat protein fhr fhr fhr addit cfh fhr recruit carboxyethyl pyrrol cep full length cfh also possess abil attenu hne induc oxid stress consequ alter innat humor defens ose predispos develop diseas associ oxid stress shown prototyp ose mda epitop mini review focus mechan accumul ose pathophysiolog consequ interact differ ose complement compon addit discuss clinic potenti genet variant ose recogn complement protein ose complotyp risk estim diseas associ oxid stress | D002097;D017242 | T129;T116 |
36,248,823 | earli immunolog respons mrna sar cov vaccin patient neuromuscular disord intramuscular inject sar cov vaccin rais concern use patient neuromuscular disord nmds evalu respons patient nmds bntb vaccin | D000086382;D009468 | T019;T047;T067 |
36,248,822 | signatur construct molecular subtyp identif base cuproptosi relat gene predict prognosi immun activ patient hepatocellular carcinoma hepatocellular carcinoma hcc one common malign world high incid high malign low surviv rate cuproptosi novel form cell death mediat lipoyl tca cycl protein mediat novel cell death pathway high associ mitochondri metabol howev relationship express level cuproptosi relat gene crgs prognosi hcc still unclear | D006528;D008113 | T191 |
36,248,821 | foot mouth diseas virus non structur protein b downregul rlr signal pathway via degrad rig mda foot mouth diseas virus fmdv singl strand posit sens rna virus contain least protein mani protein show immun modul capabl non structur protein fmdv b involv rearrang host cell membran disrupt host secretori pathway viroporin previous studi also shown fmdv b play role modul host type interferon ifn respons inhibit express rig mda key cytosol sensor type ifn signal howev exact molecular mechan poor understood demonstr fmdv b modul host ifn signal pathway degrad rig mda fmdv b target rig ubiquitin proteasom degrad recruit e ubiquitin ligas ring finger protein rnf also target mda apoptosi induc caspas caspas depend degrad ultim fmdv b signific inhibit rna virus induc ifn product import identifi c termin amino acid fmdv b essenti b mediat degrad rig mda collect result provid clearer understand specif molecular mechan use fmdv b inhibit ifn respons ration approach virus attenu futur vaccin develop | D029544;D007370 | T129;T005;T121;T116 |
36,248,820 | effect tai chi intervent nlrp relat antivir inflammatori factor serum patient pre diabet nlrp inflammasom relat antivir inflammatori factor implic pathogenesi type diabet mellitus tdm insulin resist contribut pre diabet remain poor understood | D003924;D007333;D011236;D026302 | T047;T046;T056 |
36,248,819 | blood dna methyl mark discrimin chaga cardiomyopathi diseas clinic form chaga diseas parasit diseas south america affect around million peopl worldwid decad infect peopl develop chronic form includ chronic chaga cardiomyopathi ccc treatment exist two stage character form moder form character heart eject fraction ef sever form associ ef propos two set dna methyl biomark predict blood ccc occurr ccc stage analysi base machin learn algorithm make predict accuraci test cohort beyond predict capac cpgs locat near gene involv immun respons nervous system ion transport atp synthesi pathway known deregul cccs among gene also differenti express heart tissu interest cpgs interest tag gene main involv nervous ionic process given close link methyl gene express list cpgs promis good biomark also good indic key element develop patholog | D002598;D014355 | T047 |
36,248,818 | clinic relev use complet high resolut hla type accur interpret posttranspl immun mediat graft outcom complet high resolut hr hla type improv accur assess donor recipi compat pre transplant donor specif antibodi dsa howev valu inform identifi de novo immun mediat graft event impact outcom assess donorrecipi kidney transplant pair dna sampl evalu six locus abcdrbdqbadpb hr hla type de novo anti hla antibodi assess use solid phase assay dndsa classifi either per current clinic practic accord three locus abdrb low resolut lr type estim donor hla cdq type frequenc tabl accord complet six locus hr type impact graft outcom compar group accord lr hla type patient develop dndsa lrdndsa twenti nine confirm dndsa hr type lrdndsahrdndsa wherea lrdndsahrdndsa lrdndsa specif confirm hr type wherea lr specif confirm lrdndsahrdndsa patient higher risk abmr compar dndsa lrdndsahrdndsa logrank higher risk death censor graft loss logrank lrdndsa hr ci lrdndsahrdndsa hr ci lrdndsahrdndsa independ predict graft loss implement hr hla type improv character biolog relev de novo anti hla dsa discrimin patient poorer graft outcom | D006084;D006680 | T129;T116;T042 |
36,248,817 | sar cov variant alpha beta delta omicron show slower host cell interferon respons compar earli pandem variant sinc start pandem end aris mutat sar cov improv transmiss abil circumv immun induc vaccin previous covid infect studi effect sar cov genom mutat replic innat immun give us valuabl insight evolut virus aid develop vaccin new treatment modal systemat analyz kinet virus replic innat immun activ host cell antivir respons pattern alpha beta delta kappa omicron two earli pandem sar cov variant infect human lung epitheli calu cell observ overal compar replic pattern variant modest variat particular sublineag omicron ba ba recombin sublineag xj show attenu replic calu cell compar alpha delta furthermor relat weak activ primari innat immun signal pathway howev variant produc enough interferon induc activ stat product interferon stimul gene isg interferon mrna express stat activ correl cellular viral rna level isg product although clear cut effect specif sar cov genom mutat could conclud variant concern includ omicron show lower replic effici slower interferon respons compar earli pandem variant studi | D000086382;D000086402 | T047;T005;T067 |
36,248,816 | unravel solubl immun checkpoint chronic lymphocyt leukemia physiolog immunomodul immun dysfunct chronic lymphocyt leukemia cll lymphoid neoplasm character accumul matur b cell diagnosi establish detect monoclon b lymphocyt peripher blood even earli stage monoclon b cell lymphocytosi mbl hi clinic cours high heterogen fact well character multipl prognost factor also relat observ genet heterogen immunoglobulin heavi chain variabl region ighv mutat status delp tp mutat among other moreov dysregul immun system innat adapt immun observ cll patient strong impact immun surveil consequ onset evolut therapi respons addit tumor microenviron high complex heterogen ie matrix fibroblast endotheli cell immun cell play critic role evolut cll studi quantit profil protein cytokin chemokin growthregulatori factor immun checkpoint solubl receptor serum sampl cll mbl hi systemat evalu also differenti profil solubl immun factor discrimin mbl hi cll scd scd stimd sil r sulbp diseas progress scd scd sarginas slag il sil r among profil correl prognost factor ighv mutat status cxcli tac cxclip shevm slag deciph result pave way explor role solubl immun checkpoint promis sourc biomark cll provid novel insight immun suppress process andor dysfunct most cell combin cellular balanc disrupt microenviron polar lead tumor escap | D015451 | T191 |
36,248,815 | mycobacteri acyl carrier protein suppress tfeb activ upregul mir inhibit host defens mycobacteri acyl carrier protein acpm rv key protein involv mycobacterium tuberculosi mtb mycol acid product shown suppress host cell death mycobacteri infect studi report mycobacteri acpm work effector subvert host defens promot bacteri growth increas microrna mirna p express murin bone marrow deriv macrophag bmdms acpm protein prevent transcript factor eb tfeb transloc nucleus bmdms like inhibit transcript activ sever autophagi lysosom gene although acpm suppress autophag flux bmdms acpm reduc mtb lamp co local indic acpm inhibit phagolysosom fusion mtb infect mechanist acpm boost akt mtor pathway bmdms upregul mirna p ship target mirna mirna p express inhibit bmdms acpm induc increas intracellular surviv mtb suppress addit acpm overexpress signific reduc mycobacteri clearanc chebfej mice infect recombin smegmati strain collect find point acpm novel mycobacteri effector regul antimicrobi host defens potenti new therapeut target mtb infect | D035683;D009169 | T123;T007;T114 |
36,248,814 | enlarg perivascular space neuroinflamm neurolog dysfunct nmosd patient cerebrospin fluid csf interstiti fluid exchang along brain wide network perivascular space pvs term glymphat system aquaporin aqp water channel abund express astrocyt endfeet play key role csf circul glymphat system neuromyel optica spectrum disord nmosd inflammatori demyelin autoimmun diseas central nervous system cns featur specif autoantibodi direct aqp patient anti aqp antibodi like result impair brain glymphat system enlarg pvs nmosd patient current studi aim demonstr featur epv detect mri associ csf anti aqp antibodi titer cns inflammatori marker diseas sever nmosd patient | D009471 | T047 |
36,248,813 | antithrombin activ level predict long term outcom earli phase isol traumat brain injuri coagulopathi manag import strategi prevent secondari brain damag patient traumat brain injuri tbi antithrombin natur anticoagul control coagul inflamm pathway howev signific activ level outcom patient trauma remain unclear studi aim investig relationship activ level long term outcom patient tbi sub analysi prior studi collect blood sampl trauma patient prospect tertiari care center kawaguchi citi japan includ patient isol tbi itbi age year admit direct hospit within h injuri april march general coagulofibrinolyt specif molecular biomark includ measur h injuri analyz chang activ level studi period impact activ level long term outcom glasgow outcom scale extend gose month injuri patient includ studi good neurolog outcom gose poor neurolog outcom gose low activ level shown within h injuri patient poor gose group associ poor outcom furthermor activ level h injuri strong predict valu long term outcom area receiv oper characterist curv ci multivari logist regress analysi various biomark show independ factor long term outcom adjust odd ratio ci p anoth multivari analysi sever score show low activ level associ poor outcom adjust odd ratio ci p demonstr activ level soon injuri could predictor long term neurolog prognosi patient itbi | D000991;D000070642 | T121;T116;T037 |
36,248,812 | px purinerg receptor play critic role maintain cell homeostasi prevent lupus pathogenesi sever lymphoprolif lupus diseas develop mrl lpr mice depend interact fas lpr mutat mrl genet background thus fas lpr mutat caus limit diseas cbl mice previous found accumul b cd cd doubl negat dn cell mrl lpr mice show defect px receptor px induc cellular function suggest px contribut cell homeostasi along fas therefor generat b lpr mous strain call b lpr px ko carri homozyg px knockout allel b lpr px ko mice accumul high number fasl express b dn cell cdrb high cd high effectormemori cd cell origin develop sever lupus character leukocyt infiltr tissu high level igg anti dsdna rheumatoid factor autoantibodi mark cytokin network dysregul b lpr px ko mice also exhibit consider reduc lifespan px therefor novel regul cell homeostasi cooper fas critic prevent lymphoaccumul autoimmun | D058486;D012217 | T129;T116;T192 |
36,248,811 | lymphocyt c reactiv protein ratio differenti diseas sever covid patient serv assist screen tool hospit icu admiss studi aim explor whether lymphocyt c reactiv protein ratio lcr differenti diseas sever coronavirus diseas covid patient valu assist screen tool admiss hospit intens care unit icu total adult covid patient covid treatment center heilongjiang provinc first affili hospit harbin medic univers januari march includ studi patient divid asymptomat infect group mild group moder group sever group critic group accord diagnosi treatment new coronavirus pneumonia ninth edit demograph clinic data includ gender age comorbid sever covid white blood cell count wbc neutrophil proport neut lymphocyt count lymph lymphocyt percentag lym red blood cell distribut width rdw platelet plt c reactiv protein crp alanin aminotransferas alt aspart aminotransferas ast serum creatinin scr albumin alb total bilirubin tb direct bilirubin dbil indirect bilirubin ibil dimer obtain collat medic record admiss sequenti organ failur assess sofa score lcr calcul indic compar among group multipl clinic paramet includ lymph crp lcr show signific differ among group relat factor classifi covid patient moder sever critic group includ age number comorbid wbc lcr ast among factor number comorbid show greatest effect wbc lcr protect factor area receiv oper characterist roc curv lcr classifi covid patient moder sever critic group cutoff valu lcr sensit specif roc curv respect relat factor classifi covid patient sever critic group includ number comorbid plt lcr sofa score among factor sofa score show greatest effect lcr protect factor area roc curv lcr classifi covid patient sever critic group cutoff valu lcr sensit specif roc curv respect summari lcr differenti diseas sever covid patient serv simpl object assist screen tool hospit icu admiss | D000086382 | T047;T067 |
36,248,810 | car cell therapi hematolog malign limit optim strategi past decad emerg chimer antigen receptor car cell therapi led cellular immunotherapi revolut various cancer although car cell therapi demonstr remark efficaci patient certain b cell driven hematolog malign studi requir broaden use car cell therapi hematolog malign moreov treatment failur still occur signific proport patient car antigen loss cancer cell one common reason cancer relaps addit immun evas aris due hostil immunosuppress tumor microenviron impair car cell vivo persist direct antitumor activ advers effect associ car cell therapi anoth major concern treatment newli emerg treatment approach numer novel preclin studi propos differ strategi enhanc efficaci attenu car cell associ toxic recent year major obstacl imped promis outcom patient hematolog malign car cell therapi review herein along recent advanc made surmount | D019337;D000076962 | T129;T191;T116;T192 |
36,248,809 | novel peanut specif human ige monoclon antibodi enabl screen inhibitor effector phase food allergi us resid food allergi includ peanut allergi mast cell mediat releas allergi effector phase drive allerg reaction therefor target sensit mast cell may prevent food allergi symptom | D005512;D021183 | T047;T046 |
36,248,808 | exhaust exhaust target regulatori cell tumor microenviron concept cancer immunotherapi gain immens momentum recent year advanc checkpoint blockad led notabl progress treat plethora cancer type howev approach also appear stall due factor individu genet make resist tumor sub type immun relat advers event ira major focus immunotherapi larg allevi cell intrins defect cd cell tumor microenviron tme amend relationship tumor specif cd cell cd cell start drive attent well major roadblock improv cross talk cd cell cd cell immun suppress action tumor infiltr regulatori treg cell despit indispens protect tissu autoimmun threat treg also scrutini help tumor thrive review address treg establish tme suppress anti tumor immun particular delv factor promot treg migrat tumor tissu discuss uniqu cellular humor composit tme aid surviv differenti function intratumor treg furthermor summar potenti suppress mechan use intratumor treg discuss way target ultim guid new immunotherapi | D009369;D059016 | T191;T070 |
36,248,807 | immunogen cell death relat regul classif pattern immun microenviron infiltr character intracrani aneurysm base machin learn immunogen cell death icd novel way regul cell death suffici activ adapt immun respons role immun still emerg howev involv icd intracrani aneurysm ia remain unclear studi aim identifi biomark associ icd determin relationship immun microenviron onset progress ia | D024243;D024241;D002532 | T123;T116;T190;T047;T046 |
36,248,806 | genet associ leukocyt telomer length grave diseas biobank japan two sampl mendelian random studi telomer length tl recogn fundament risk autoimmun disord howev role leukocyt tl grave diseas yet fulli elucid studi exploit two sampl mendelian random mr design evalu causal effect leukocyt tl risk grave diseas | D006111;D057182 | T062;T047 |
36,248,805 | allergen plant calmodulin artemisia pollen prime human dcs lead th polar artemisia pollen major caus season allerg respiratori diseas northern hemispher artemisia allerg patient ige recogn artcam novel allergen calmodulin artemisia identifi studi patient exhibit stronger allerg reaction longer durat allerg symptom howev signal mechan trigger allerg reaction fulli understood studi found extracellular artcam direct induc matur human dendrit cell dcs attribut seri ca relev cascad includ ca nfatcamk artcam alon induc inflammatori respons toward th th treg interest combin artcam anti artcam ige led th polar putat mechan anti artcam ige partial block artcam induc erk signal affect ca depend cascad crosstalk erk ca signal prime dcs matur th polar summari artcam relat clinic symptom combin anti artcam ige could novel allergen activ dcs promot th polar find provid mechanist insight th polar allerg sensit pave way novel prevent therapeut strategi effici manag pollen allerg diseas | D019306;D003713;D006967;D018418 | T046;T025;T002 |
36,248,804 | home alon antigen present cell cell communic barrier tissu prime cell antigen present cell apc essenti cell fate decis enabl cell migrat specif tissu exert effector function previous interact main explor use blood deriv cell anim model great advanc singl cell rna sequenc techniqu enabl analysi tissu deriv cell becom clear subset apc respons prime modul heterogen cell effector respons differ tissu composit apc cell tissu essenti maintain homeostasi known skew infect inflamm lead patholog cell respons review highlight common differ cell prime subsequ effector function multipl barrier tissu skin intestin femal reproduct tract provid overview process alter tissu specif infect known caus chronic inflamm knowledg could har modifi cell respons barrier tissu | D000938;D013601 | T025 |
36,248,803 | third dose mrna sar cov vaccin enhanc spike specif antibodi memori b cell respons myelofibrosi patient vaccin sar cov use mrna base vaccin high recommend fragil subject includ myelofibrosi patient mf avail data immun respons mf patient mrna sar cov vaccin impact therapi jak inhibitor ruxolitinib still fragment profil spike specif igg memori b cell respons mf patient treat ruxolitinib second third dose sar cov bntb biontech mrna moderna vaccin plasma peripher blood mononuclear cell sampl collect vaccin post second third dose test spike specif antibodi acerbd antibodi inhibit bind activ spike specif b cell third vaccin dose signific increas spike specif igg titer ruxolitinib treat untreat patient strong enhanc percentag subject antibodi capabl vitro block acerbd interact low frequenc spike specif b cell measur blood day second vaccin dose strong signific increas elicit third dose administr generat b cell respons similar one detect healthi control despit overal posit impact third dose mf patient two patient activ concomit immunosuppress treatment time vaccin patient receiv lymphodeplet therapi past remain low respond third mrna vaccin dose strong increas sar cov specif humor b cell respons mf patient promot reactiv immun respons similar one observ healthi control | D000086382;D000075242;D055728;D014765 | T129;T121;T067;T191;T047 |
36,248,802 | ovo model cancer research tumor immunolog consid cancer malign cell complex diseas tumor cell interact communic microenviron motiv establish clinic relev model past year technolog advanc gave rise novel bioengin model improv organoid system microfabr approach increas scientif import preclin research notwithstand mammalian vivo model remain closest mimic patient situat limit cost time ethic constraint herein ovo model bridg gap advanc model basic translat cancer research without need ethic approv avian embryo natur immunodefici host tumor cell primari tissu engraft vascular chorioallanto membran cam high effici regardless speci specif restrict extraembryon membran connect embryo continu circulatori system readili access manipul longitudin monitor tumor growth metastasi angiogenesi matrix remodel howev applic immunoncolog research larg underexplor dual engraft malign immun cell could provid platform studi tumor immun cell interact complex heterogen dynam microenviron high reproduc caveat keep mind versatil method ex ovo monitor cellular molecular dynam alreadi establish ovo applic alik view present review aim emphas discuss opportun limit chicken embryo model pre clinic research cancer cancer immunolog | D049033;D009369 | T018;T191 |
36,248,801 | system biolog artifici intellig analysi highlight pleiotrop effect ivig therapi autoimmun diseas predomin role b cell complement system intraven immunoglobulin ivig use treatment sever autoimmun inflammatori condit specif mechan fulli understood herein aim evalu use system biolog artifici intellig techniqu differ pathophysiolog pathway autoimmun inflammatori condit show divers respons ivig treatment also intend determin target ivig involv best treatment respons evalu diseas select classif diseas base previous publish systemat review perform diseas character manual curat literatur furthermor undertook mechanist evalu artifici neural network pathway enrich analys set diseas select classifi compar result indic diseas clear benefit ivig treatment main character deregul process b cell complement system inde result show protein relat b cell complement system pathway target ivig involv clinic respons addit target relat immun process may also play import role ivig respons support wide rang action sever mechan although b cell respons complement system key role diseas benefit ivig protein target involv process necessarili diseas therefor ivig appear pleiotrop effect may involv collabor particip sever protein broad spectrum target non specif ivig could key efficaci differ diseas | D001327;D016756 | T129;T047;T121;T116 |
36,248,800 | explain artifici intellig precis medicin acut myeloid leukemia artifici intellig ai unveil novel person treatment base drug screen whole exom sequenc experi wes howev concept black box ai limit potenti approach translat clinic practic contrast explain ai xai focus make ai result understand human present novel xai method call multi dimension modul optim mom associ drug screen genet event guarante predict interpret robust appli mom acut myeloid leukemia aml cohort ex vivo tumor sampl screen drug wes mom return therapeut strategi base flt cbf myh nras status predict aml patient respons quizartinib trametinib selumetinib crizotinib success valid result three differ larg scale screen experi believ xai help healthcar provid drug regul better understand ai medic decis | D001185;D015470 | T090;T191;T073;T066 |
36,248,799 | identif valid gene signatur improv surviv predict glioma glioma one frequent type nervous system tumour signific morbid mortal rate result critic fulli comprehend molecular mechan glioma predict prognosi target gene therapi goal research discov hub gene glioma investig prognost diagnost use studi collect mrna express profil clinic inform glioma patient tcga gtex gse gse databas wgcna differenti express analysi identifi deg collect dataset go kegg pathway analys reveal deg main enrich gliogenesi extracellular matrix lasso perform construct prognost signatur tcga cohort gene use build risk model valid cgga databas roc curv confirm accuraci prognost signatur univari multivari cox regress analys show independ risk factor glioma except gender next perform ssgsea demonstr high correl risk score immun subsequ hub gene identifi ppi network found great drug target potenti final rpl one hub gene found close relat prognosi glioma patient knockdown rpl vitro signific inhibit prolifer migrat glioma cell wherea overexpress rpl opposit effect found knockdown rpl inhibit polar infiltr phenotyp macrophag conclus new prognosi relat model provid potenti therapeut strategi glioma patient | D005910 | T191 |
36,248,798 | downregul long noncod rna hcpmir pzeb axi inhibit malign biolog function laryng squamous cell carcinoma cell previous studi find long noncod rna human leukocyt antigen complex p hcp regard oncogen via acceler cancer cell growth invas metastasi vascular drug resist renal cell carcinoma gastric cancer colorect cancer nevertheless effect regulatori mechan hcp laryng squamous cell carcinoma lscc remain unknown studi hcp express level confirm promin rais lscc cell line hcp knockdown reduc cell prolifer migrat invas abil lscc cell line furthermor mir p confirm spong hcp express promin downregul lscc cell line upregul hcp silenc lscc cell line mir p overexpress downregul cell prolifer migrat invas abil lscc cell addit protein level zinc finger e box bind homeobox zeb one target gene mir p high express lscc cell line express level downregul hcp knockdown mir p overexpress mir p inhibitor revers effect hcp knockdown prolifer migrat invas abil lscc cell conclus knock hcp may strategi suppress malign biolog function via regul mir pzeb therefor hcp may becom prospect therapeut target lscc | D006258;D035683;D062085 | T123;T191;T114 |
36,248,797 | reestablish immun toler rheumatoid arthriti rheumatoid arthriti ra chronic progress autoimmun diseas despit wide use convent synthet target biolog diseas modifi anti rheumat drug dmard control radiolog progress near dmard immunolog non select address under immunolog mechan ra patient ra often need take various dmard long term even lifelong thus face increas risk infect tumor advers reaction logic modul immun disord restor immun balanc patient ra restor immun toler inde approach base stem cell transplant tolerogen dendrit cell toldc antigen base tolerogen vaccin activ investig alreadi transform wet bench research clinic investig last decad among clinic trial stem cell therapi especi mesenchym stem cell mscs transplant investig follow toldc ra patient hand despit activ laboratori investig use ra specif peptid protein base tolerogen vaccin cell clinic studi ra patient much limit overal preliminari result clinic studi promis encourag demonstr safeti effect rebalanc cell subset particular recoveri ra specif treg increas anti inflammatori cytokin reduc proinflammatori cytokin futur studi focus optim transplant stem cell prepar toldc tolerogen vaccin ra specif protein peptid includ dosag cours rout administr well coordin multi center random clinic control research progress experiment clinic studi generat restor ra specif immun toler may bring revolutionari chang clinic manag ra near futur | D018501;D001172;D001688 | T121;T047;T123 |
36,248,796 | efficaci effect safeti herp zoster vaccin immunocompet immunocompromis subject systemat review network meta analysi investig efficaci effect safeti recombin zoster vaccin rzv zoster vaccin live zvl immunocompet immunocompromis subject | D006562;D053061 | T129;T047;T121 |
36,248,795 | cgasst innat brain inflamm follow acut high fat feed obes prediabet diabet grow preval worldwid metabol disord associ neurodegen diseas particular alzheim diseas alzheim diseas relat dementia innat inflammatori signal play critic role associ potenti via earli activ cgasst pathway determin acut system metabol inflammatori respons correspond chang brain use high fat diet fed obes mous model prediabet cognit impair observ acut system chang metabol inflammatori respons impair glucos toler insulin resist alter peripher immun cell popul central inflammatori chang includ microgli activ pro inflammatori environ cgasst activ block gap junction neuron microgli co cultur signific decreas cgasst activ collect studi suggest role earli activ innat immun system peripher central potenti inflammatori crosstalk neuron glia | D000544;D004660;D011236 | T047;T048 |
36,248,794 | identif valid common pathogenesi hub biomark hirschsprung diseas complic crohn diseas although increas evid support hirschsprung diseas hscr risk factor children develop crohn diseas cd common mechan co occurr remain unknown purpos studi explor under mechan biomark co occurr hscr cd | D003424;D006627 | T019;T047 |
36,248,793 | specif circul neutrophil subset present clinic stabl adult cystic fibrosi modul pulmonari exacerb progress lung destruct cystic fibrosi cf tight associ chronic bacteri infect neutrophil domin airway inflamm cf pulmonari diseas complic episod acut exacerb contribut irrevers lung damag hypothes circul subset neutrophil clinic stabl adult cf present phenotyp specif could amplifi activ infecti episod aim present studi examin differ neutrophil subset whole blood low densiti neutrophil ldn co purifi peripher blood mononuclear cell pbmc clinic stabl adult cf cf adult pulmonari exacerb compar healthi donor blood sampl obtain adult cf stabl state pulmonari exacerb healthi donor flow cytometri analysi differ marker relat lineag cd cd matur cd cd cd activ cdl cdb cdb cd metabol glut lox immunosuppress pd pd l carri within whole blood within ldn fraction unsupervis analysi flow cytometri data perform use visual distribut stochast neighbor embed vi tsne signific increas cdb express neutrophil cf patient exacerb observ compar neutrophil stabl cf patient healthi donor indic circul activ state due infecti status percentag ldn increas stabl cf patient increas exacerb analysi neutrophil subset use doubl cdcdl label reveal signific increas cd high cdl low subset cf patient compar healthi donor contrast increas cd low cdl high subset observ cf patient exacerb unsupervis analysi identifi pd l high cd high popul present stabl cf patient well cf patient exacerb | D003550;D009504 | T047;T025 |
36,248,792 | sle classif criteria scienc base icon algorithm distract intellectu demand dilemma say prerog author assign sle classif criteria allow declar someth definit import sle particular true criteria base classif process overrul high need evolut concis diagnost criteria classif criteria alloc sle patient cohort intend describ natur diseas therefor major sle classif criteria sinc preliminari criteria usurp role diagnost criteria today practic silent accept sle classif process diagnos sle patient despit fact classif criteria accept diagnost criteria central paradox contemporari sle research strategi contemporari sle cohort design investig sles etiolog featur howev cohort categor classif criteria one central inher problem theoret practic argument embodi multipl distinct clinic phenotyp rais critic princip question phenotyp heterogen sle cohort use identifi basic sle specif etiolog ie diseas process es time come must priorit develop firm diagnost criteria sle classif criteria contribut reduc enigmat charact syndrom radic improv visibl horizon may lead concis investig sle well defin homogen sle cohort must develop new strategi studi phenotyp standard cohort sle must central element problem relat contemporari sle classif criteria contempl analyz critic discuss studi | D008180 | T047 |
36,248,791 | immunolog studi covid vaccin candid base recombin spike trimer protein differ sar cov variant concern emerg new sar cov variant featur increas immun escap mark urgent demand better vaccin provid broader immunogen evalu immunogen capac vaccin candid base recombin trimer spike protein differ sar cov variant concern voc includ ancestr wuhan beta delta virus particular assess formul contain either singl combin protein variant studi show formul contain singl protein ancestr wuhan virus concentr g sw vac g display mous model highest igg antibodi level three wuhan beta delta sar cov protein variant test addit formul induc signific higher neutral antibodi titer three viral variant compar author gam covid vac radrad sputnik v chadox astrazeneca vaccin sw vac g also abl induc ifn gamma il memori cd popul follicular cell use booster dose schedul perform differ author vaccin sw vac g vaccin candid also induc higher level total igg igg isotyp protein differ sar cov variant comparison observ homolog dose schedul sputnik v astrazeneca moreov sw vac g booster induc broad strong neutral antibodi level three test sar cov variant sw vac g booster also induc cd central memori cd effector cd popul overal result demonstr sw vac g promis formul develop next generat covid vaccin | D000086382;D000086663 | T200;T047;T067 |
36,248,790 | impact platelet pulmonari microcircul throughout covid persist activ factor patient covid often hypoxemia impair lung function abnorm imag manifest acut convalesc stage alveolar inflamm pulmonari vascul thromboembol synergist damag blood air barrier result increas pulmonari permeabl gas exchang disord incid low platelet count correl diseas sever platelet also involv impair pulmonari microcircul lead abnorm lung function differ phase covid activ platelet lose abil protect integr blood vessel wall increas permeabl pulmonari microvasculatur high level platelet activ marker observ mild sever case short long term therefor risk thrombot event may alway present vascular endotheli injuri immun cell inflammatori mediat hypoxia particip high reactiv aggreg platelet various way microvesicl phosphatidylserin ps platelet coagul factor close relat releas various cell deriv microvesicl detect covid patient addit provid phospholipid surfac synthesi intrins factor xase complex prothrombinas complex expos ps also promot decrypt tissu factor tf promot coagul activ complex factor viia activ factor x treatment covid hypercoagul thrombosi still focus earli intervent antiplatelet therapi play role reliev diseas inhibit format hypercoagul state reduc thrombot event mortal improv sequela ps anoth potenti target inhibit hypercoagul state | D000086382;D003029;D013927 | T121;T047;T046;T067 |
36,248,789 | decreas peripher basophil count urticaria mous model oxazolon induc hypersensit latter suggest basopenia reflect migrat skin decreas number basophil peripher blood basopenia note reflect activ chronic spontan urticaria csu infiltr basophil skin also report mechan basopenia csu clarifi phenomenon basopenia activ phase urticaria confirm basophil number increas follow symptom improv patient treat omalizumab patient treat antihistamin examin immunostain also reveal basophil infiltr csu lesion previous report sinc patient alreadi take oral steroid consid appropri examin relationship basophil number tissu peripher blood use mous model contact hypersensit singl applic oxazolon known stimul basophil infiltr investig basophil count skin peripher blood bone marrow model decreas peripher blood basophil number observ one day challeng day reflect supplement bone marrow inde cultur basophil express gfp transplant peripher blood gfp posit basophil number peripher blood remain low even day challeng despit differ among speci model result suggest one reason decreas basophil peripher blood csu may involv migrat circul basophil skin | D000080223;D014581 | T047 |
36,248,788 | pd inhibit plus platinum base chemotherapi pbc pbc alon first line treatment local advanc metastat pulmonari lymphoepithelioma like carcinoma pulmonari lymphoepithelioma like carcinoma plelc distinct subtyp non small cell lung carcinoma well present clinic studi manag advanc plelc remain import unmet need due pauciti high grade evid herein carri multicent retrospect studi assess effect toler pd pd l inhibitor plus chemotherapi versus chemotherapi alon patient advanc plelc first line set | D002294;D008175 | T191 |
36,248,787 | singl domain antibodi applic bacteri infect diagnosi neutral increas antibiot resist bacteri infect caus serious threat human health effici detect treatment strategi key prevent reduc bacteri infect due high affin antigen specif antibodi becom import tool diagnosi treatment various human diseas addit convent antibodi uniqu class heavi chain antibodi hcab found serum camelid shark hcab bind antigen one variabl domain refer vhh variabl domain heavi chain hcab recombin format vhh also call singl domain antibodi sdab nanobodi nb shark might also ancestor hcab sdab v nar might engin compar tradit ab nbs sever outstand properti small size high stabil strong antigen bind affin high solubl low immunogen furthermor express low cost microorgan amen engin superior properti make nbs high desir altern convent antibodi extens employ structur biolog unravel biochem mechan molecular imag diagnosi treatment diseas review summar recent progress nanobodi base approach diagnosi neutral bacteri infect discuss challeng nbs field | D001424;D002161;D061905 | T129;T047;T015;T116 |
36,248,786 | assess plasma catestatin covid reveal hitherto unknown inflammatori activ impact morbid mortal neuroendocrin cell releas catestatin cst chromogranin cga regul stress respons regard covid patient covid requir oxygen suppli date nobodi studi cst potenti mediat regul immun | D000086382 | T047;T067 |
36,248,785 | pan cancer analysi aim inflammasom potenti implic immunotherapi human cancer bulk omic research singl cell sequenc valid absent melanoma aim inflammasom multi protein platform recogn aberr cytoplasm doubl strand dna dsdna induc cytokin matur releas pyroptosi studi found aim inflammasom doubl edg sword mani cancer howev fewer studi aim inflammasom pan cancer | D058847;D008545 | T123;T191;T116 |
36,248,784 | associ microbi indoleamin dioxygenas deriv tryptophan metabolit immun activ healthi adult tryptophan trp metabolit intestin bacteria indol indol acet acid iaa indol propion acid ipa trp metabolit kynurenin kyn indoleamin dioxygenas ido pathway aryl hydrocarbon receptor ahr agonist thus regul immun activ via ahr pathway hypothes plasma concentr metabolit would associ marker immun activ cohort healthi adult manner consist ahr mediat immun regul also hypothes plasma kyntrp ratio marker ido activ would associ immun marker reflect ido activ innat immun cell final hypothes intestin bacteria would associ plasma indol ipa iaa bacteria would associ immun marker | D007737;D014364 | T121;T123;T116;T109;T046 |
36,248,783 | chang advers event report follow immun hepat b vaccin among infant vaccin administr law china hepat b vaccin hepb routin recommend part immun program china satisfactori safeti effect profil protect infant hepat b virus infect evalu surveil sensit chang time aefi report relat hepb among infant base consist nation data introduct vaccin administr law law china | D000707;D006509 | T047;T046 |
36,248,782 | associ immun relat advers event efficaci pd inhibitor advanc esophag cancer recent develop immun checkpoint inhibitor ici improv treatment outcom esophag cancer ec howev may initi immun relat advers event ira patient ici therapeut efficaci associ ira patient non small cell lung cancer renal cell carcinoma although associ unknown ec purpos studi explor associ ira efficaci program death pd inhibitor ec patient | D002289;D064420;D004938;D007154;D008175 | T047;T191;T037;T046 |
36,248,781 | preoper system inflammatori respons index predict long term outcom type b aortic dissect endovascular repair inflamm hallmark initi develop progress aortic dissect studi aim investig valu preoper inflammatori biomark predict aorta relat advers event aae thorac endovascular aortic repair tevar type b aortic dissect | D000784;D017545;D057510 | T061;T047;T046 |
36,248,245 | review herbal medicin base phytochem garcinia molecular therapi breast cancer data globocan statist indic breast cancer becom highest incid rate cancer estrogen receptor er progesteron receptor pr human epiderm growth factor receptor known immunohistochemistri ihc marker mediat cell growth surviv signal furthermor regul protein receptor downstream signal pathway emerg critic compon breast cancer format prolifer becom well establish therapeut target core focus breast cancer therapi research garcinia big genus clusiacea famili contain wide spectrum biolog activ metabolit chemic composit isol fruit stem bark seed leav root result includ polyisoprenyl benzophenon polyphenol bioflavonoid xanthon lacton triterpen review articl aim analyz potenti garcinia phytochem molecular therapi breast cancer result show phytochem garcinia ie mangostin cambogin gambog acid ga garcinol griffipavixanthon friedolanostan triterpenoid hexan neobractatin epiclusianon xanthochymol guttiferon e isoxanthochymol cycloxanthochymol anticanc properti includ apoptosi inhibit prolifer metastasi review import provid inform regard phytochem garcinia altern treatment breast cancer patient articl select articl research base inclus criteria keyword garcinia breast cancer english avail full text abstract search pubm | D029760;D009369;D010946;D014315;D044004 | T121;T191;T002;T109 |
36,248,244 | exosom deriv hypox glioma cell reduc sensit glioma cell temozolomid carri mir p hypoxia frequent featur solid tumor signific affect efficaci treatment chemotherapi addit exosom hypox cancer cell could contribut chemoresist tumor cell carri mirna shown mir p level upregul glioma howev whether exosom deriv hypox glioma cell could affect temozolomid tmz resist glioma carri mir p remain unexplor | D055354;D005910;D035683 | T026;T123;T191;T114 |
36,248,243 | novel compound biolog activ deriv soil fungi past decad secondari metabolit isol soil fungi receiv attent especi new compound exhibit good biolog activ review total new compound includ relev literatur sinc new compound isol soil fungi divid compound seven categori includ alkaloid terpenoid steroid keton phenylpropanoid quinon ester lacton etc addit biolog activ structur activ relationship compound also fulli discuss activ compound rough divid eight categori includ anticanc activ antimicrobi activ anti inflammatori activ antioxid activ antivir activ antimalari activ immunosuppress activ activ sinc natur product import sourc new drug review may posit guid effect drug screen | D000470;D000962;D001688 | T123;T121;T131;T109 |
36,248,224 | metabol syndrom associ factor among type diabet patient southwest ethiopia metabol syndrom one lead global public health clinic challeng increas preval figur rang high fold increas metabol syndrom associ type diabet fold increas associ develop cardiovascular diseas calori dens diet sedentari life pattern import contributori factor establish | D003924;D024821 | T047 |
36,248,223 | network pharmacolog transcriptom reveal mechan gualouqumaiwan treatment type diabet activ small molecular compound main pathophysiolog abnorm type diabet td includ pancreat cell dysfunct insulin resist due hyperglycemia patient receiv long term treatment howev side effect drug toler usual lead treatment failur gualouqumaiwan glqmw common tradit chines medicin tcm prescript posit effect control blood sugar improv qualiti life mechan still unclear deciph molecular mechan use novel comput system pharmacolog base approach consist bioinformat analysi network pharmacolog drug similar comparison divid particip nondiseas nd impair glucos toler igt type diabet group accord recommend diabet analyz gene express profil nd igt td nd igt td process found function downregul gene whole process main relat insulin secret upregul gene relat inflamm furthermor gene nd igt nd igt process main relat inflamm lipid metabol disord specul gene consist trend may play key role process nd igt td perform target predict compound glqmw met screen criteria intersect differenti express gene td process compound glqmw total protein prove potenti target glqmw among rbp consider relat insulin resist gokegg enrich analys target gene glqmw show enrich inflamm td therapi relat pathway base rdkit tool drugbank databas specul taxifolin dialosid aqt spinasterol isofucosterol eicosadieno acid use potenti drug td via molecular dock drug similar comparison | D003924;D018149;D007333 | T047;T046 |
36,248,210 | gender affirm mastectomi trend surgic outcom adolesc transgend adolesc unit state yet research outcom follow gender affirm mastectomi age group limit evalu gender affirm mastectomi incid well postop complic includ regret adolesc within integr health care system | D001943;D057830;D063106 | T061;T191;T098 |
36,248,192 | famb novel biomark mediat tissu immun microenviron pulmonari arteri hypertens purpos studi uncov potenti diagnost indic pulmonari arteri hypertens pah evalu function immun cell pathogenesi diseas find innov treatment target medicin potenti enhanc prognosi gene express omnibus util acquir pah dataset recogn differenti express gene deg investig function util r softwar weight gene coexpress network analysi least absolut shrinkag select oper support vector machin use identifi biomark extent immun cell infiltr normal pah tissu determin use cibersort addit associ diagnost marker immun cell analyz studi deg use analyz diseas ontolog deg link atherosclerosi arteriosclerot cardiovascular diseas lung diseas includ obstruct lung diseas gene set enrich analysi reveal compar normal sampl result pah patient most associ ecm receptor interact arrhythmogen right ventricular cardiomyopathi wnt signal pathway focal adhes famb identifi biomark pah area curv mechan under pah may mediat nave cd cell rest memori cd cell rest nk cell monocyt activ dendrit cell rest mast cell neutrophil accord investig immun cell infiltr famb express also associ rest mast cell monocyt cd cell result suggest pah may close relat famb high diagnost perform associ immun cell infiltr suggest famb may promot progress pah stimul immun infiltr immun respons studi provid valuabl insight pathogenesi treatment pah | D000081029 | T047 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.